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In this study, the prognostic significance of tumor metrics derived from diffusion tensor imaging (DTI) was
evaluated in patients with locally advanced breast cancer undergoing neoadjuvant therapy. DTI and con-
trast-enhanced magnetic resonance imaging were acquired at 1.5 T in 34 patients before treatment and af-
ter 3 cycles of taxane-based therapy (early treatment). Tumor fractional anisotropy (FA), principal eigenval-
ues (1, 2, and 3), and apparent diffusion coefficient (ADC) were estimated for tumor regions of interest
drawn on DTI data. The association between DTI metrics and final tumor volume change was evaluated with
Spearman rank correlation. DTI metrics were investigated as predictors of pathological complete response
(pCR) by calculating the area under the receiver operating characteristic curve (AUC). Early changes in tu-
mor FA and ADC significantly correlated with final tumor volume change post therapy (  0.38, P  .03
and   0.71, P  .001, respectively). Pretreatment tumor ADC was significantly lower in the pCR than in
the non-pCR group (P  .04). At early treatment, patients with pCR had significantly higher percent changes
of tumor 1, 2, 3, and ADC than those without pCR. The AUCs for early percent changes in tumor FA
and ADC were 0.60 and 0.83, respectively. The early percent changes in tumor eigenvalues and ADC were
the strongest DTI-derived predictors of pCR. Although early percent change in tumor FA had a weak associa-
tion with pCR, the significant correlation with final tumor volume change suggests that this metric changes
with therapy and may merit further evaluation.
INTRODUCTION
There is increasing clinical interest in the use of magnetic res-
onance imaging (MRI) techniques to evaluate tumors in patients
with locally advanced breast cancer (LABC) who are receiving
(preoperative) neoadjuvant chemotherapy (NACT). The ability to
predict response at an early time point in treatment could po-
tentially allow for modification of treatment to improve efficacy
and decrease morbidity.
Although change in tumor size has been shown to be a
surrogate predictor of response to chemotherapy (1), changes in
tumor morphology tend to occur later in therapy and after
biological effects such as changes in tumor microvasculature or
cellular density (2, 3). Diffusion-weighted imaging (DWI) is an
MRI technique that is being investigated as a potential bio-
marker of early response to treatment. DWI has the advantage of
not requiring administration of a contrast agent, and echo pla-
nar imaging-DWI enables relatively short image acquisition
times. DWI uses diffusion-sensitizing gradients to characterize
the magnitude of water motion within tissue and thus indirectly
provide information about tissue cellularity and microstructure.
The apparent diffusion coefficient (ADC) is a quantitative mea-
sure of water mobility calculated from DWI images.
Previous DWI studies have found that the ADC in breast
tumors is reduced relative to the ADC in normal tissue, and this
difference is correlated with an increase in cell density in tumors
(4, 5). DWI has been shown to increase diagnostic accuracy of
malignant breast lesions in combination with dynamic contrast-
enhanced (DCE)-MRI (6, 7). In a DWI study of patients with
breast cancer undergoing NACT, an increase in tumor ADC was
shown to precede a decrease in tumor size (3). Other DWI studies
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of patients receiving NACT have found that pretreatment tumor
ADC and early change in tumor ADC were associated with final
tumor volume response (8) or pathological complete response
(pCR) (9).
More recently, the breast has been studied with diffusion
tensor imaging (DTI), which is sensitive to both the magnitude
and direction of water motion. DTI uses a minimum of 6 non-
collinear gradient directions to characterize the full diffusion
tensor and calculate the 3 main eigenvalues of the diffusion
tensor (1, 2, and 3), allowing for the estimation of the
directionality (anisotropy) of water diffusion within tissue in
addition to mean diffusivity (ADC). Fractional anisotropy (FA) is
a commonly used DTI-derived metric that reflects the degree of
directionality of diffusion. In tissues where diffusion is isotropic,
that is, 1  2  3, the theoretical value of FA is zero,
whereas if diffusion occurs principally along 1 direction and is
highly restricted in the other directions, FA will approach the
maximum value of 1.
An initial study of breast cancer using DTI found that FA
was lower in breast tumors than in normal breast fibroglandular
tissue, and that FA provided increased diagnostic accuracy over
ADC alone (10). It was hypothesized that the lower FA in tumors
may be attributable to a disruption of the organized structure of
normal breast parenchyma, characterized by a network of ducts
and lobules supported by stroma, caused by the disorganized
growth and increased cellularity of tumors (10). Subsequent DTI
studies of breast have reproduced the finding of lower FA in
tumors (11, 12); however, other studies have found no difference
in FA between tumor and normal tissue (13, 14). To date, little
has been reported on the effects of treatment on DTI-measured
metrics in breast tumors.
In this preliminary work, the prognostic significance of DTI
was evaluated in patients with LABC undergoing NACT. In
particular, the associations between tumor DTI metrics and the
following two measures of tumor response were investigated:
(1) change in tumor volume at the end of NACT; and
(2) tumor pCR, which is a clinical measure of tumor response.
METHODS
Patient Population
Patients with biopsy-confirmed LABC undergoing NACT con-
sisting of 12 weekly cycles of taxane-based therapy followed by
Adriamycin–Cytoxan (AC) treatment, were enrolled in institu-
tional review board-approved, Health Insurance Portability and
Accountability Act-compliant clinical trials at our institution.
All patients gave informed consent. MRI was performed for each
patient on the following 4 separate visits: before the start of
NACT (MRI1, pretreatment); after the third weekly cycle of pac-
litaxel treatment (MRI2, early treatment); after the final cycle of
paclitaxel treatment but before the start of AC treatment (MRI3,
inter-regimen); and after the completion of AC treatment and
before surgery (MRI4, presurgery). Patients were scanned using a
standard DCE-MRI protocol, and a subset of patients was also
scanned with DTI. In total, 40 women who were scanned with
both DCE-MRI and DTI were included in this study. The data
from 6 patients were excluded because of DTI scan protocol
deviations; so, the final study cohort included 34 patients.
MRI Data Acquisition
All MRI data were acquired on a 1.5 T GE Signa HDx scanner (GE
Healthcare, Waukesha, Wisconsin) using an 8-channel bilateral
phased array breast coil (Invivo Corp., Gainesville, Florida [for-
merly Sentinelle Medical, Toronto, Canada]). Bilateral DCE-MRI
images were acquired in the axial orientation using a 3-dimen-
sional fast gradient echo sequence with the following parameters:
repitition time (TR) 7 (ms), echo time (TE) 4.2 ms, flip angle
10°, and Array Spatial Sensitivity Encoding Technique (ASSET)
parallel imaging acceleration factor 2. Field of view varied from
280 to 360 mm to achieve full bilateral coverage. Patients received
0.1 mmol/kg body weight of gadopentetate dimeglumine (Magn-
evist, Bayer Healthcare Pharmaceuticals, Berlin, Germany) contrast
agent.
Bilateral, axial diffusion tensor images were acquired
after DCE-MRI, using a fat-suppressed single-shot echo pla-
nar DWI sequence with the following parameters: TR  6000
ms, TE  69.6 ms, field of view  400  400 mm, acquisition
matrix  128  128, slice thickness  3 mm, slice skip  0
mm, number of signal averages  6, and ASSET factor  2.
Diffusion gradients were applied in 6 directions with b
values  0 and 600 s/mm2. The image acquisition time was
4.3 minutes.
DTI Data Analysis
Parametric maps of the 5 rotationally invariant DTI metrics—
mean diffusivity (Davg), also referred to as ADC; maximum
tensor eigenvalue (1); intermediate tensor eigenvalues (2);
minimum (3) tensor eigenvalues; and FA—were calculated
from DTI data based on the methods of Basser and Pierpaoli (15),
using in-house software developed in IDL (ITT Visual Informa-
tion Solutions, Boulder, Colorado). The ADC reflects the magni-
tude of water mobility and was calculated using equation (1) as
follows:
ADC
1 2 3
3
mm2⁄second (1)
FA is a unitless measure that reflects the degree of direc-
tionality of diffusivity, and was calculated using equation (2) as
follows:
FA
(1 2)2 (2 3)2 (3 1)2
212 22 32
(2)
An ROI for each tumor was manually defined on a repre-
sentative slice of the MRI1 and MRI2 diffusion tensor images by
a radiologist with 7 years of experience in evaluating breast
MRIs. The ROIs were subsequently reviewed by an MRI scientist
with 13 years of experience in evaluating breast MRIs and one
with 1 year of experience, to ensure that ROIs encompassed only
tumor tissue; this resulted in modification of 3 of the ROIs.
Tumor ROIs were drawn to encompass areas that were hyperin-
tense on b  600 s/mm2 combined images and hypointense on
corresponding ADC maps. Enhancing areas on corresponding
DCE-MRI subtraction images (precontrast subtracted from post-
contrast) were also used to guide ROI selection. Clip artifacts and
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areas of necrosis were excluded from the ROIs. Mean and me-
dian tumor FA; 1, 2, and 3; and ADC values were calculated
from the corresponding parametric maps for each ROI. The mean
difference between the maximum and minimum eigenvalues
(1–3) for tumor was also calculated. Tumor DTI metrics were
calculated for time points MRI1 and MRI2, and the early treat-
ment percent changes in DTI metrics [(MRI2  MRI1)/MRI1) 
100] were also calculated. Additionally, an ROI was drawn for
each patient in normal-appearing breast fibroglandular tissue
on the contralateral breast, whenever possible on the same DTI
slice in a similar location within the unaffected breast (similar
anterior/posterior offset and right/left offset) as the tumor. These
ROIs were used to calculate mean FA and ADC values for normal
breast tissue.
Response Assessment: Tumor Final Volume Presurgery
and Tumor Pathology Postsurgery
Functional tumor volume (FTV) for each imaging visit was
calculated from DCE-MRI using a previously described semiau-
tomated segmentation method for calculating the volume of all
tumor voxels that exceeded a percent enhancement threshold of
70% at the second postcontrast time point (16). The FTV analysis
was performed by 2MRI scientists with 10 years of experience,
and all segmentations were reviewed and approved by the des-
ignated breast radiologist at our institution. The early treatment
percent changes in FTV (FTV2, from MRI1 to MRI2) and the
final percent change in FTV, after completion of NACT and
before surgery (FTVNACT, from MRI1 to MRI4), were calculated
for statistical analysis.
The pathological response to NACT was assessed after sur-
gery by gross and microscopic examination of the excised tumor
specimens, and then classified into 2 groups—pCR or non-pCR.
In our study, pCR was defined as no residual invasive disease
(17). Information on tumor histological grade, estrogen and
progesterone receptor, HER-2/neu, and lymph node metastasis
was obtained from histopathological reports.
Statistical Analysis
An unpaired t-test was used to estimate the difference between
mean ages in pCR and non-pCR groups, based on the assump-
tion that age followed a normal distribution. The Fisher exact
test was used to estimate associations between histological sub-
type, hormone receptor, HER-2/neu, lymph node metastasis, and
pCR versus non-pCR.
The Shapiro–Wilk test was used to test the normality of
tumor DTI-measured metrics and MRI volume. Differences in
DTI-measured metrics were evaluated between tumor and nor-
mal tissue with the Wilcoxon signed rank test. Spearman’s
rank-order correlation coefficient  was used to assess the as-
sociation between MRI-derived tumor metrics (FA, eigenvalues,
ADC, and volume) measured at MRI1 and MRI2, (including early
percent changes between MRI1 and MRI2) and the final percent
tumor volume change at MRI4 (FTVNACT). The Mann–Whitney
U-test was used to evaluate differences in MRI-measured tumor
metrics between the pCR and non-pCR groups. Data were ex-
pressed as median with interquartile ranges.
A receiver operating characteristic (ROC) curve was used to
assess the performance of MRI-measured tumor metrics in dif-
ferentiating pCR from non-pCR, and the areas under the ROC
curve (AUCs) were calculated. Further, the 95% confidence in-
tervals were calculated for AUCs with 2000 stratified bootstrap
replicates. Two-tailed statistical tests were always used, and
findings with a P-value .05 were considered statistically sig-
nificant. Statistical analysis was performed using R: a language
and environment for statistical computing (Vienna, Austria)
(18).
RESULTS
Patients
A total of 34 lesions in 34 patients (mean age, 48.1 years; range,
32–70 years) who underwent definitive surgery after completing
NACT were evaluated with DTI in addition to DCE-MRI from
September 2010 to June 2012. Patient characteristics are shown
in Table 1. Histopathological assessment of surgical specimens
collected after completion of NACT found that 25 of 34 (73.5%)
patients had residual invasive disease and were classified as
non-pCR, whereas 9 (26.5%) were classified as pCR with no
evidence of invasive disease. Of the 9 patients with pCR, 6
(66.7%) showed no evidence of malignant cells and 3 (33.3%)
showed ductal carcinoma in situ only. Pathology showed inva-
sive ductal carcinoma in 33 patients (97.1%) and mixed ductal
and lobular carcinoma in 1 patient (2.9%). No significant dif-
ference in patient age was found between the pCR and non-pCR
groups. Significant associations with pCR outcome were found
for estrogen receptor status and lymph node metastasis. Due to
the small sample size, we did not adjust for estrogen receptor
status or lymph node metastasis in our statistical analysis.
FA and ADC in Tumor and Normal Breast
Fibroglandular Tissue: Full Cohort
The mean pretreatment (MRI1) FAs for tumor and normal breast
fibroglandular tissue for the full cohort were 0.18  0.06 and
0.21  0.06, respectively. The mean early treatment (MRI2) FAs
for tumor and normal fibroglandular tissue were 0.21  0.05 
103 mm2/s and 0.22 0.07, respectively. The FA of tumor was
significantly lower than that of fibroglandular tissue before
treatment (MRI1; P  .03), but not at early treatment (P  .4).
The FA of tumor of the full cohort was significantly higher at
MRI2 than at MRI1 (P  .003).
The mean pretreatment (MRI1) ADCs for tumor and normal
fibroglandular tissue for the full cohort were 1.15  0.15 
103 mm2/s and 2.05  0.25  10-3 mm2/s, respectively. The
mean early treatment (MRI2) ADCs for tumor and normal fi-
broglandular tissue for the full cohort were 1.51  0.22  103
mm2/s and 2.07 0.23 103 mm2/s, respectively. The ADC of
tumor was significantly lower than that of fibroglandular tissue
at both time points (P  .0001), and the ADC of tumor at MRI2
was significantly higher than that at MRI1 (P  .0001).
Correlation of Tumor MRI Metrics and Final Tumor
Volume Change: Full Cohort
Spearman rank correlation test found no statistically significant
associations between pretreatment (MRI1) tumor MRI metrics
and percent FTV change after NACT (FTVNACT); results are
Diffusion Tensor Imaging of Breast Cancer Treatment Response
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shown in Table 2. At the early treatment time point (MRI2),
significant correlations with FTVNACT were found for 1 (P 
.005), 2 (P  .006), 1–3 (P  .01), and ADC (P  .001), with
 ranging from 0.42 to 0.47.
Statistically significant correlations with FTVNACT were
also found for the early percent changes in all tumor MRI
metrics, with strong and significant correlations found for the
following diffusivity measures: 1, 2, 3, and ADC, with 
ranging from 0.65 to 0.73 and P .001 for all measures
(Table 2). Moderate and significant correlations were found for
early percent changes in 1–3 (  0.43, P  .007) and FA
(  0.38, P  .03) and for early percent change in tumor
volume, FTV2 (  0.39, P  .02).
No significant association was found between tumor FA
and tumor ADC at either MRI1 (  0.03, P  .86) or MRI2 ( 
0.2, P  .3). However, a statistically significant correlation was
found between the early percent change in tumor ADC and the
early percent change in FA (  0.42, P  .01).
Comparison of Pre- and Early Treatment Tumor MRI
Metrics Between pCR and Non-pCR Groups
At the pretreatment time point (MRI1), patients in the pCR
group had significantly lower tumor 2 (P  .05) and ADC
(P  .04) than those in the non-pCR group (Table 3).
Although 1 and 3 were also lower in the pCR group, these
differences were not significance. At the early treatment time
point (MRI2), no significant differences in tumor MRI metrics
were found (Table 3).
The early percent changes in the following tumor MRI
metrics were found to be statistically significantly higher in the
pCR versus the non-pCR group: 1 (P .004), 2 (P .008), 3
(P  .009), and ADC (P  .002) (Table 3). No statistically
significant differences between the pCR group and the non-pCR
group were found for the early percent change in tumor FA (P
.42) or FTV (P  .49). The early percent changes in tumor FA,
ADC, and FTV for the pCR and non-pCR groups are summarized
in the plots in Figure 1. Although the early percent change in the
Table 1. Clinical Characteristics of Patients and Lesions (N  34)
Characteristics pCR (n  9) Non-pCR (n  25) P-Value
Age (years), mean (range) 51.9 (39–70) 46.8 (32–64) 0.14
Menopausal status 0.65
Premenopausal 5 13
Perimenopausal 0 4
Postmenopausal 4 8
Surgery method 0.70
Mastectomy 3 11
Breast-conserving surgery 6 14
Histological subtype 1
Invasive ductal carcinoma 9 24
Mixed ductal and lobular carcinoma 0 1
Estrogen receptor 0.026
Negative 0 7
Positive 5 16
NA 4 2
Progesterone receptor 0.06
Negative 2 12
Positive 3 11
NA 4 2
HER-2/neu 0.31
Negative 2 12
Positive 2 7
Indeterminate (FISH) 1 2
NA 4 4
Lymph node metastasis 0.006
Negative 3 12
Positive 2 13
NA 4 0
Abbreviations: pCR, pathological complete response; NA, not available.
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Table 2. Association of Pre- and Early Treatment DTI- and DCE-Derived Metrics With %Change in Functional Tumor
Volume Post Treatment (FTVNACT) Assessed With Spearman Rank Correlation ()
MRI Metric
Tumor
MRI1 MRI2
%Change
MRI1 to MRI2
 (P-Value)  (P-Value)  (P-Value)
FA 0.004 (.98) 0.21 (.24) 0.38 (.03)a
1 0.09 (.6) 0.47 (.005)a 0.65 (.001)a
2 0.28 (.1) 0.46 (.006)a 0.73 (.001)a
3 0.21 (.2) 0.33 (.06) 0.68 (.001)a
1–3 0.05 (.8) 0.42 (.01)a 0.46 (.007)a
ADC 0.21 (.22) 0.45 (.001)a 0.71 (.001)a
FTV 0.14 (.42) 0.38 (.03)a 0.39 (.02)a
Abbreviations: DCE, dynamic contrast-enhanced; DTI, diffusion tensor imaging; FTV, functional tumor volume; FA, fractional anisotropy; ADC, apparent
diffusion coefficient; MRI, magnetic resonance imaging.
aStatistically significant correlations (P  .05).
Table 3. Comparison of Tumor FA, Principal Eigenvalues, ADC, and Volume Between pCR and Non-pCR Groups
for MRI1, MR2 and %Change MRI1 to MRI2
MRI Tumor Metric
pCR Non-pCR
M IQR M IQR P-Value
MRI1 (Pretreatment)
FA 0.15 0.14, 0.19 0.17 0.15, 0.20 .62
1 1.25 1.11, 1.35 1.35 1.26, 1.45 .06
2 1.04 0.96, 1.09 1.14 1.08, 1.20 .05a
3 0.87 0.77, 0.95 0.96 0.89, 1.00 .09
1–3 0.30 0.26, 0.45 0.40 0.33, 0.46 .3
ADC 1.07 0.98, 1.10 1.15 1.09, 1.19 .04a
FTV 8.3 4.8, 19.3 24.4 8.0, 36.1 .20
MRI2 (Early treatment)
FA 0.21 0.18, 0.23 0.21 0.17, 0.21 .82
1 1.77 1.66, 2.05 1.74 1.58, 1.98 .5
2 1.56 1.38, 1.63 1.45 1.33, 1.64 .8
3 1.15 1.13, 1.31 1.18 1.07, 1.31 .6
1–3 0.62 0.51, 0.86 0.60 0.47, 0.77 .7
ADC 1.50 1.40, 1.68 1.43 1.33, 1.65 .59
FTV 7.4 2.5, 16.2 6.1 3.4, 17.2 .89
%Change MRI1 to MRI2
FA 28.0 12.3, 32.1 16.5 5.0, 29.0 .49
1 55.9 47.2, 62.0 30.1 21.9, 42.0 .004a
2 52.6 43.8, 57.6 25.6 21.1, 42.5 .008a
3 44.2 35.0, 45.7 21.3 14.5, 30.8 .009a
1–3 89.2 69.7, 116.6 45.9 35.2, 75.0 .07
ADC 53.2 43.9, 57.2 26.4 20.0, 40.5 .002a
FTV 46.6 72.8, 10.7 54.8 72.5, 26.2 .42
Abbreviations: pCR, pathological complete response; IQR, interquartile range; MRI, magnetic resonance imaging; FA, fractional anisotropy; ADC, apparent
diffusion coefficient; FTV, functional tumor volume.
Data represent the median value of the metric (M) and the interquartile range (IQR).
aStatistically significant differences with P  .05.
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pCR group appears higher than that for the non-pCR group for
all 3 MRI metrics, only the percent ADC change was signifi-
cantly different between the 2 groups.
Representative images from DCE-MRI (early postcon-
trast) and DTI are shown for MRI1 and MRI2 time points for a
tumor that was classified as pCR (Figure 2) and for a tumor
that was classified as non-pCR (Figure 3). For DTI, the b 
600 image and the corresponding FA and ADC parametric
maps are shown with the tumor ROI delineated. For these 2
examples, a visible change in FA between MRI1 and MRI2 is
difficult to appreciate for either the pCR tumor (Figure 2, C
and G) or the non-pCR tumor (Figure 3, C and G). For the
tumor ADC maps, the values throughout the tumor generally
increase between MRI1 and MRI2 for the pCR tumor (Figure 2,
D and H); however, no such change is visibly apparent in the
non-pCR tumor (Figure 3, D and H).
Figure 1. Box plots of early per-
cent change in tumor fractional
anisotropy (FA), apparent diffu-
sion coefficient (ADC), and vol-
ume between pathological com-
plete response (pCR) and non-
pCR groups. Early percent
change of FA was not signifi-
cantly different between the 2
groups (P  .49) (A). Early per-
cent change in ADC in the pCR
group was significantly higher
than that in the non-pCR group (P
 .002) (B). No significant differ-
ence was found for early percent
change in tumor volume between
the pCR and non-pCR groups (C).
Figure 2. Example images from
a patient with locally advanced
breast cancer (LABC) who was
categorized as pCR based on
postsurgical pathology. Dynamic
contrast-enhanced magnetic reso-
nance imaging (DCE-MRI) sub-
traction images (precontrast sub-
tracted from early postcontrast)
and diffusion tensor imaging (DTI)
images (b  600, FA map, and
ADC map) are shown for the pre-
treatment time points (A, B, C,
and D) and early treatment time
points (E, F, G, and H). The tu-
mor region of interest (ROI) is
indicated by the contour line on
the DTI b  600 images and FA
and ADC maps, and colorized
maps of the FA and ADC values
within the tumor ROI are also
shown.
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Association of Pre- and Early Treatment Tumor MRI
Metrics With pCR
The AUCs and confidence intervals from ROC curve analysis of
tumor MRI metrics for the pre- and early treatment time points
are shown in Table 4. The following were the pretreatment MRI
metrics that had statistically significant associations with pCR:
2 and ADC, with AUCs of 0.72 and 0.74. Pretreatment 1 and
3 AUCs were in a similar range, but these did not reach
statistical significance. None of the MRI metrics showed a sig-
nificant association with pCR for the early treatment (MRI2) time
point. The early percent changes (MRI1 to MRI2) in 1, 2, 3,
and ADC were all statistically significantly associated with pCR,
with AUCs of 0.82 0.80, 0.79, and 0.83 respectively. FA mea-
sures were not statistically significantly associated with pCR,
with the highest AUC of 0.58 found for early percent change in
FA. Similarly, early time point measures for FTV did not achieve
significance, with the highest AUC value for tumor volume
being 0.65 for pretreatment FTV.
DISCUSSION
In this preliminary study, DTI-derived tumor metrics (FA, prin-
cipal eigenvalues and ADC) and DCE-MRI tumor volume metrics
were measured in patients with LABC undergoing NACT before
and after 3 cycles of taxane-based therapy. The associations
between these tumor MRI metrics and treatment response as
characterized by final FTV change post NACT (FTVNACT) and
pCR were evaluated. Early percent change in all tumor MRI
metrics showed a significant correlation with FTVNACT. Of the
Table 4. AUCs of Pre- and Early Treatment MRI-Derived Tumor Metrics for Predicting pCR
MRI Tumor Metric
MRI1 MRI2
%Change
MRI1 to MRI2
AUC CI AUC CI AUC CI
ADC 0.74a 0.51, 0.96 0.56 0.34, 0.79 0.83a 0.61, 1.00
FA 0.56 0.31, 0.81 0.53 0.30, 0.76 0.58 0.34, 0.82
FTV 0.65 0.42, 0.88 0.52 0.30, 0.74 0.60 0.35, 0.85
1 0.72 0.50, 0.93 0.57 0.34, 0.80 0.82a 0.61, 1.00
2 0.72 0.49, 0.95 0.54 0.32, 0.76 0.80a 0.57, 1.00
3 0.70 0.46, 0.93 0.44 0.24, 0.64 0.79a 0.56, 1.00
1–3 0.72 0.50, 0.93 0.57 0.34, 0.80 0.71 0.47, 0.95
Abbreviations: AUC, areas under the ROC curve; CI, confidence interval; MRI, magnetic resonance imaging.
aAUCs 	0.5, with P  .05.
Figure 3. Example images from
a patient with LABC who was cat-
egorized as non-pCR based on
postsurgical pathology. DCE-MRI
subtraction images (precontrast
subtracted from early postcontrast)
and DTI images (b  600, FA
map, and ADC map) are shown
for the pretreatment time points
(A, B, C, and D) and early treat-
ment time points (E, F, G, and H).
The tumor ROI is indicated by the
contour line on the DTI b  600
images and FA and ADC maps,
and colorized maps of the FA
and ADC values within the tumor
ROI are also shown.
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tumor metrics evaluated, the early percent changes in tumor
principal eigenvalues and ADC had the strongest associations
with pCR.
The pretreatment tumor FA, principal eigenvalues, and ADC
values measured in this patient cohort were within the ranges
measured in other diagnostic DTI studies of the breast using the
same MRI field strength and b values (10, 12). Consistent with
previous breast DTI studies (10–12), the pretreatment ADCs in
this patient cohort were found to be significantly lower in
tumors than in normal tissue. The lower tumor ADC values are
also consistent with previous DWI studies of breast cancer (4,
19). Tissues with higher cell density are expected to have more
restricted water mobility, and the lower ADC in breast tumors
has been shown to correlate with increased cell density (20). The
pretreatment tumor FA in this cohort was significantly lower
than that in normal breast fibroglandular tissue. This is consis-
tent with the hypothesis that breast tumors represent a disrup-
tion of normal breast tissue structure and is in agreement with
some DTI studies of breast tumors (10–12, 21). Although other
DTI studies in breast have reported no differences in FA between
tumor and normal fibroglandular tissue (13, 14), these were
diagnostic studies in which tumor sizes are generally not as
large as in the setting of LABC. Measurement of DTI metrics in
larger tumors may be less affected by partial volume effects
from adjacent tissue that can hinder differentiation of tumor
from normal tissue.
The association between pre- and early treatment tumor
MRI metrics and change in FTV after NACT was evaluated
because FTV change has been shown to be a predictor of recur-
rence-free survival (1, 22). At the early treatment time point
(MRI2), the tumor diffusivity measures, 1, 2, 1–3, and ADC,
had statistically significant correlations with FTVNACT. FTV
measured at MRI2 also had a significant, but weaker, correlation
with final tumor volume change.
Interestingly, significant correlations were found between
the early percent changes in all tumor MRI metrics and
FTVNACT. The strongest significant (negative) correlations were
found for early percent change in tumor 1, 2, 3, and ADC.
The correlation between early percent change in ADC and post-
treatment tumor volume is in agreement with some previous
DWI studies of patients with breast cancer undergoing NACT
(23), although other DWI studies of NACT have not found such
a correlation (3, 24). Moderate statistically significant correla-
tions were found for 1–3, FA, and FTV2.
The association between MRI tumor metrics and pCR was
evaluated because pCR has been established as an indepen-
dent prognostic marker for overall survival in breast cancer
and is currently the gold standard for assessing response to
NACT (25). Patients displaying complete disappearance of the
tumor at surgical pathology after NACT have favorable over-
all survival rates and decreased risk of recurrence (26-28). At
the pretreatment time point (MRI1) 2 and ADC were statis-
tically significantly lower in the pCR group. The tumor ADC
finding is consistent with other published work that found
that lower pretreatment breast tumor ADC measured by DWI
was associated with treatment response in patients undergo-
ing NACT (8, 23); however, not all studies have found this
association (3, 24).
The early percent changes in tumor 1, 2, 3, and ADC
were all significantly higher in the pCR group than in the
non-pCR group. The early percent change in tumor ADC for
the pCR group (53.2%) in this study was comparable with
results from another study, which found a significantly
greater increase in tumor ADC in patients with breast cancer
in the pCR versus non-pCR groups after 4 cycles of 5-fluo-
rouracil epirubicin cyclophosphamide NACT (9). The early
percent increases in tumor 1 and 2 in the pCR group were
also comparable with the early percent increase in tumor ADC
found in the pCR group. The early-treatment percent in-
creases found for tumor 1, 2, and 3 had fairly narrow
ranges for both the pCR and non-pCR groups, (56% to 44%
and 30% to 21%, respectively), suggesting that the 3 orthog-
onal eigenvectors increased symmetrically, at least during
the early treatment phase.
Although the early percent change in tumor FA was greater
for the pCR group than for the non-pCR group, this difference
was not significant. Both tumor ADC and FA were statistically
significantly higher in the full cohort post treatment, and early
changes in both metrics were significantly associated with
FTVNACT; however, only the change in ADC was significantly
associated with pCR. Although it can be hypothesized that
neoadjuvant treatment may affect tissue microstructure and
organization in a way that may be reflected in changes in both
tumor ADC and FA, to date, little has been published on the
effects of NACT on breast tumor DTI metrics such as FA and
eigenvalues.
One recent abstract using DTI to assess early changes in
ADC and FA in patients with advanced breast cancer receiv-
ing AC NACT found a significant increase in tumor ADC, but
no significant change in tumor FA, after 1 cycle of therapy
(29). Another DTI abstract measured changes in tumor ADC
and FA at early and later time points in patients with breast
cancer receiving NACT, and found that although ADC was
significantly increased in responders at the early treatment
time point, a significant increase in FA was not observed until
the later treatment time point (30). These findings suggest
that changes in tumor FA may occur at different time points
compared with tumor ADC and may be dependent on the type
of treatment.
The lack of significant association of FA parameters with
pCR status may also be reflective of the higher within-subject
coefficient of variation that has been found for FA (11.4%)
compared with that for ADC (4.5%) (31). In addition, the criteria
used to draw the tumor ROI may affect FA values more than
ADC values. In the study by Balzter et al. (11), evaluating DTI in
breast lesions and normal breast fibroglandular tissue, two types
of tumor ROIs were drawn: one encompassing the whole tumor
on the b  1000 images and the other including only the
brightest areas from the original whole-tumor ROI. The FA
measured from the tumor ROI type that encompassed the whole
tumor was not significantly different from normal breast tissue
FA, whereas the FA measured from the tumor ROI type that
encompassed only the brightest areas was significantly lower
than the FA from the normal breast tissue. When both types of
tumor ROIs were applied to ADC maps, the mean tumor ADCs
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were slightly different; however, significant differences between
tumor ADC and normal breast tissue ADC were found for both
tumor ROI types. Thus, the criteria used to select the tumor ROI
may also affect the sensitivity of the FA measurement.
There are several limitations to the current study. One
limitation is the relatively small number of patients scanned
with DTI. In addition, a limitation of standard single shot-
echo planar imaging-DWI sequences is that the spatial reso-
lution is relatively low (ie, larger voxels) compared with
gradient echo sequences commonly used for DCE-MRI. As a
consequence, tissue partial volume effects may limit the abil-
ity of DTI metrics, in particular those measuring anisotropy,
to detect response. It has been suggested that imaging tech-
niques with higher spatial resolution may improve the pre-
dictive value of DTI in breast (11). Another potential limita-
tion is the use of a single slice ROI to characterize each tumor
rather than a multi-slice ROI that may better reflect the full
range of tumor values for DTI metrics. Finally, the timing of
the early treatment measurement may not have been optimal
for evaluating changes in tumor FA.
In conclusion, this study found that of all the DTI metrics
evaluated, the early percent changes in tumor principal eigenvalues
and ADC had the strongest associations with pCR, and these mea-
sures were stronger predictors than early changes in FTV. Although
early percent change in tumor FA had aweak associationwith pCR,
the significant correlation of early percent change in FA with final
tumor volume change suggests that this parameter may provide
additional information on tumor response and may merit further
evaluation in a larger patient cohort. Future DTI studies may ben-
efit from assessing changes at a later time point during treatment,
as changes in FA and ADC may not occur at the same rate. The
utilization of more advanced DTI techniques, with reduced distor-
tion and/or improved spatial resolution, that are now becoming
commercially available, may also improve the ability to detect
differences in FA between tissues and treatment-induced changes
in FA within a tissue over time.
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